OncoMatch/Clinical Trials/NCT07125391
Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer
Is NCT07125391 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Cohort A for ovarian cancer.
Treatment: Cohort A — Ovarian Cancer (OC) is one of the most common gynecological malignant tumors. In recent years, the incidence of ovarian cancer in China has been on the rise, but its mortality ranks the first among gynecological tumors. Cytoreductive Surgery (CRS) combined with chemotherapy is the standard treatment for patients with advanced ovarian cancer. However, most of the ovarian cancer is stage Ⅲ and above, and there may be a certain degree of organ metastasis. Preclinical studies have found that the stress of melanoma block beta adrenergic signals in mice, which USES beta blockers, checkpoint will enhance resistance to PD - 1 the activity of the inhibitor, to improve the treatment of mice on the immune response. Non-selective β-blockers can also improve the efficacy of melanoma immunotherapy. Retrospective studies have shown that incidental use of β-blockers in combination with antiangiogenic agents, chemotherapy, and immune therapy can prolong DFS, PFS, and OS in cancer patients. A large, multicenter retrospective study found that ovarian cancer patients who took nonselective β-blockers for hypertension had better survival than those who did not. In conclusion, this study aims to explore new auxiliary chemotherapy combined propranolol treatment of high efficacy and safety of ovarian cancer, provide more evidence-based basis for clinic.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Disease stage
Required: Stage FIGO STAGE III, FIGO STAGE IV (FIGO)
Grade: high-grade
FIGO stage for stage III or IV, including not surgery in patients with stage III or IV beginning for ovarian cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: pelvic radiotherapy
Always received pelvic radiotherapy and systemic chemotherapy for ovarian cancer, tumor targeting therapy, immune therapy
Cannot have received: systemic chemotherapy
Always received pelvic radiotherapy and systemic chemotherapy for ovarian cancer, tumor targeting therapy, immune therapy
Cannot have received: tumor targeting therapy
Always received pelvic radiotherapy and systemic chemotherapy for ovarian cancer, tumor targeting therapy, immune therapy
Cannot have received: immune therapy
Always received pelvic radiotherapy and systemic chemotherapy for ovarian cancer, tumor targeting therapy, immune therapy
Lab requirements
Blood counts
hemoglobin (HGB) 90 g/L or higher; Neutrophils (NEUT) acuity 1.5 x 10^9 / L or white blood cell count (WBC) or 3 x 10^9 / L; Platelet (PLT) or 90 x 10^9 / L
Kidney function
Serum creatinine 1.0 x ULN or less
Liver function
AST 2.5 x ULN or less; ALT 2.5 x ULN or less; Total bilirubin 1.5 x ULN or less
Cardiac function
No severe heart dysfunction; resting ECG without significant rhythm/conduction abnormalities; no unstable angina or congestive heart failure (NYHA grade 2 or more)
Enough organ function, without severe hematopoietic dysfunction and heart, lung, liver, kidney dysfunction, and immune deficiency, participants need to satisfy the following laboratory indicators
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify